¡°	oxycodone api	14.351832134716922
	Grunenthal GmbH	12.986652090469128
¡°	oxycodone hydrochloride manufacturer	10.704578619967263
¡°	oxycodone salt	10.555956791482442
¡°	low abuk oxycodone product	8.964672267320783
¡°	oxycodone API product	8.329065889289389
¡°	oxycodone free base	7.893185444093109
	8ï¿½\ isomer	7.068167195613904
¡°	Original OxyContin	5.820034799469318
	8ï¿½]	4.489660243366842
¡°	oxycodone active pharmaceutical ingredient API product	4.188953831711551
	Rhodes Technologies	3.8515094492408455
¡°	OxyContin Antitrust Litig	3.753520845221372
¡°	Reformulated OxyContin (r) product	2.8419917540551363
	Rhodes laboratory	2.5824353711472634
	PEO	2.244830121683421
	opioid product	2.088646068486679
	popular opioid analgesic	1.9864835687652076
	hydrogenation reaction	1.5462598204176432
	another hydrogenation step	1.541716796593725
	ABUK level	1.442416273642375
	Casner	1.2851923062923758
	abuser	1.2851923062923758
	pestle	1.2851923062923758
	low ABUK Patents	1.1581091699624015
	first thebaine	1.069776273694696
	wrinkled paper	1.0125571397252564
	double hydrogenation process	0.9268091548543677
	ketone	0.7413329027675166
	crushing	0.6428401152627001
	Oxycodone hydrochloride	0.5958855704059577
	beta	0.5167769661932687
	8ï¿½\")-a diastereomer	0.5068236452228119
	opium poppy	0.4285600768418001
	collateral estoppel	0.37942748880774724
	reformulate version	0.3720613069569703
	tapentadol dosage form	0.36236120893848317
	abuse deterrent property	0.3257025478988099
	abuse deterrent technology	0.3246779005770368
	entire tablet	0.2804432333362176
	OROS technology	0.2479803030150295
	paper stock	0.20989566884608232
	push compartment	0.20963950475870297
	hydrochloric acid	0.20455420767213142
	low alpha	0.20358751146362772
	pain reliever	0.2028334880555227
	oxidation step	0.17931163290460894
	severe pain	0.1460333989974533
	problem unequal speed	0.13578105184682857
	gravity	0.1278469484023985
	dismissal	0.1278304981587648
	acid catalyze dehydration	0.12099866394077763
	completion	0.10732621132221074
	dissolution	0.10732621132221074
	Ireco	0.10732621132221074
	hard outer shell	0.09382882709166643
	high molecular weight polyethylene oxide	0.09217502559074338
	Johnson Johnson osmotically control release oral delivery system	0.09012988053559455
	abuse resistant formulation	0.08884166032497923
	particular impurity	0.08520451809617813
	District Court Decision	0.08345689545613534
	break strength test	0.08248538305329073
	high speed	0.08187283461991716
	particular isomer	0.08148268181017264
	abuse resistant property	0.07864801579627866
	consolidated appeal	0.07152366612737474
	FDA approval	0.07062086397666822
	potentially dangerous compound	0.0704212666847188
	powder	0.06934242681192125
	doctor	0.06934242681192125
	scientist	0.06896964531521113
	workable solution	0.06703455580693418
	improve formulation	0.06424645739614607
	negotiation	0.061177418923120806
	misuse	0.061177418923120806
	quality paper	0.05638373870629498
	consolidated Hatch Waxman proceeding	0.056028097413574326
	certainty	0.05437350901126193
	filing	0.04793521570209879
	joint venture	0.04235889448246136
	substantially speed	0.04045669708304082
	widespread abuse	0.040126858275060504
	FDA mandate	0.040038511630932826
	Appellees	0.039645624507385666
	pharmaceutical development	0.03891542819977086
	final salt	0.03658414267083863
	Prost	0.03584866385407612
	appx	0.032645255160546456
	propose generic product	0.031715640156296604
	generic pharmaceutical product	0.030103420890695048
	Abbreviated New Drug Applications	0.027900889793600683
	pretrial purpose	0.027190660526220132
	pressure	0.02581732054562452
	experimentation	0.02560274157341345
	non precedential decision	0.025582769550312513
	FDA protection	0.025451496904295302
	exist paper make machine	0.02138792250295221
	inner core	0.019907653375637168
	extremely low level	0.018882405905900415
	angle	0.018303071438841256
	I. Invalidity	0.017439434630587836
	every molecule	0.01712280289697528
	iv relevant secondary consideration	0.015404378254116
	twelve hour period	0.015396303784846587
	Appellants	0.014913173762882537
	similar lawsuit	0.012595329583225947
	low risk	0.012394106154822181
	scientific literature	0.012001968933644441
	force	0.011123258074382358
	relief	0.010783999018378582
	III	0.008158112389521889
	New York	0.007902721917933698
	multi district litigation	0.00764538600462471
	minor modification	0.007619821392262635
	market generic version	0.007460982331620937
	minimal amount	0.00742486304345069
	large dose	0.007369753788615224
	procedural history	0.006884179358803149
	anticipation	0.006770953366973334
	Interferences determination	0.0065863624906024355
	Idaho Board	0.006431478887776578
	label	0.006160945966564997
	Southern District	0.006153876238264405
	potential existence	0.006147742723458943
	U.S. Food Drug Administration	0.0059762372399075414
	water	0.005711844193784715
	ANDA	0.005600859101716032
	LLC	0.005292723029274275
	Board decision	0.004825209921181653
	reduction	0.00455639273794665
	three week bench trial	0.004169450138826015
	i.	0.0038639895360818217
	nonobviousness	0.003355842015313302
	significant public attention	0.0030714203029534597
	certain condition	0.0027688837145578068
	skilled artisan	0.002619989614214214
	November	0.002484358945475591
	high level	0.001902915166778442
	Obviousness	0.0017655804312980755
	June	0.0017555902648372273
	April	0.0016708941864284816
	report	0.001596047696452959
	non obvious source	0.0015452441442550323
	January	0.0013711441321800138
	six action	0.0012641130200122823
	three step	0.0011176346750928954
	asserted	0.0009449362999648871
	July	0.0008781283880058444
	none	0.0007570965914672719
	second step	0.0007115818994662557
	March	0.0006527439803956216
	September	0.0006527439803956216
	benefit	0.0005061172550172619
	October	0.00048481416689780555
	end product	0.0004666941696317742
	multiple different	0.0004194157942209299
	content	0.00035923824994967294
	owner	0.00034148602784193064
	day	0.0003233478180383243
	underlie factual inquiry	0.00025338505013278726
	focus	0.00024935176267083597
	Supreme Court	0.00024019563282762064
	cause	0.00019465689348932268
	underlie finding	0.00019313991863611007
	every limitation	0.00017492403521528435
	response	0.00016410106276301532
	three remain action	0.00013230582035161112
	three remain case	0.0001320805884361864
	court ultimate legal conclusion	0.00012928248745671978
	defendant	0.00011684967622301334
	final judgment	0.00010332054426144244
	prior art method	8.013326518797999e-05
	four	7.094876666853364e-05
	least portion	6.837285924896552e-05
	addition	6.749573472549818e-05
	background	6.167976523685923e-05
	obviousness determination	5.6257085697055714e-05
	U.S. Patent Trademark Office	3.9522799474518e-05
	district court ruling	3.695794262769198e-05
	clear error	3.695062164394277e-05
	de novo	3.233578140031489e-05
	holding	3.1701201426407455e-05
	ordinary skill	2.9618270450292427e-05
	three case	2.9518819436258256e-05
	jurisdiction	2.615851252246707e-05
	single prior art reference	1.4266757700894027e-05
	order	1.3557425273514689e-05
	way	1.0608618492448013e-05
	court finding	3.118795546570383e-06
	district court decision	2.0401106195331003e-06
	subject matter	1.738185605816615e-06
	argument	9.609816849491633e-07
	Patent Appeals	7.741635034749063e-07
	district court conclusion	7.02837537936063e-07
	evidence	1.273870293001884e-07
	invention	4.4038035681137544e-09
	issue	1.2706521754968028e-09
	Inc.	0.0
	Fed	0.0
